Short Bowel Syndrome Market Size to Grow at a CAGR of 20.52% during 2024-2034, Impelled by Advancements in Early Detection

Short Bowel Syndrome Market Outlook 2024-2034:

The short bowel syndrome market size is expected to exhibit a CAGR of 20.52% during 2024-2034. The market is driven by advances in regenerative medicine, which targets to regenerate or replace damaged intestinal tissue using stem cells and tissue engineering. Additionally, the development of targeted therapies and innovative treatments is further propelling the market growth.

Advances in Early Detection and Diagnostic Technologies: Driving the Short Bowel Syndrome Market 

Advances in early detection and diagnostic technologies are significantly contributing to the growth of the short bowel syndrome (SBS) market by enabling timely diagnosis and effective management of this complex gastrointestinal condition. Modern diagnostic approaches, including advanced imaging technologies like contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI), have revolutionized the detection of SBS. These tools provide detailed visualization of the remaining bowel anatomy, helping clinicians assess the extent of intestinal loss and plan interventions. Advanced imaging techniques also aid in monitoring the condition over time, ensuring that complications such as bowel obstruction or bacterial overgrowth are identified early. Furthermore, biomarker research is playing an increasingly prominent role in the early detection of SBS. Blood tests that measure nutritional markers, electrolyte levels, and inflammatory indicators provide critical insights into the patient’s physiological status, enabling personalized management strategies. Non-invasive tests for gut permeability and microbiota composition are emerging as supplementary diagnostic tools, offering insights into bowel functionality and the underlying causes of malabsorption. Pediatric-specific diagnostic advancements are also notable, as SBS frequently affects newborns and infants following surgery for congenital or acquired conditions. Early detection through neonatal screening and imaging technologies has improved outcomes in this vulnerable population. Additionally, telemedicine platforms are expanding access to diagnostic services, particularly for patients in remote areas, ensuring timely care. These advancements in early detection and diagnostics are not only improving patient outcomes but also driving demand for therapeutic solutions, positioning the SBS market for significant growth.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of novel therapies and pharmacological treatments is significantly driving the expansion of the short bowel syndrome market, addressing unmet needs, and improving the quality of life for patients with this challenging gastrointestinal condition. Moreover, glucagon-like peptide-2 (GLP-2) analogs have emerged as a cornerstone in SBS treatment. These agents, such as teduglutide, stimulate intestinal growth, enhance nutrient absorption, and reduce PN requirements. The success of GLP-2 therapies has not only improved patient outcomes but also spurred further research into next-generation analogs with enhanced efficacy and fewer side effects. Regenerative medicine is another transformative area in SBS management. Stem cell-based therapies and tissue-engineering approaches aim to restore intestinal function or replace lost bowel segments. Research into bioengineered intestines offers hope for curative solutions, particularly for patients with severe disease. Additionally, adjunct therapies, including probiotics, prebiotics, and microbiome-targeted treatments, are gaining attention for their potential to optimize gut health and improve nutrient absorption. These therapies complement traditional treatments by addressing underlying dysbiosis and promoting intestinal adaptation. Besides this, advances in drug delivery systems are further enhancing the efficacy of pharmacological treatments. Innovations such as extended-release formulations and localized drug delivery minimize systemic side effects and improve patient adherence. Moreover, these advancements are transforming the treatment landscape, driving significant growth in the SBS market, and offering hope for improved outcomes in this complex condition.

Marketed Therapies in Short Bowel Syndrome Market

Gattex (Teduglutide): Takeda 

Gattex (teduglutide) is a subcutaneous injectable used to treat adult patients with short bowel syndrome. The drug was developed and manufactured by NPS Pharmaceuticals in association with Takeda Pharmaceuticals. Gattex is made up of the human glucagon-like peptide 2 (GLP-2). The medicine activates GLP-2 receptors in the gut, resulting in the production of insulin-like growth factor, nitric oxide, and keratinocyte growth factor. This supports healing and proper growth of the intestinal mucosa by improving crypt depth and villi height.

NutreStore (Glutamine): Emmaus Medical

NutreStore is an amino acid used to treat short bowel syndrome in patients with specialized nutritional support when combined with an approved recombinant human growth hormone. Glutamine is considered a conditionally essential amino acid due to its decreased quantities and increased metabolism in tissues during catabolic disease conditions. NutreStore is utilized to promote muscle tissue growth and protection, as well as energy storage and immune system performance.

Zorbtive (Somatropin): Merck Serono

Zorbtive (somatropin) is a human growth hormone produced using recombinant DNA technology. Zorbtive is authorized to treat short bowel syndrome in individuals with a specific diet. The intestinal mucosa has growth hormone and insulin-like growth factor-1 ((IGF-1) receptors, which play a role in several cellular functions. Growth hormones can affect the gut directly or indirectly through IGF-1 synthesis, both locally and systemically. Somatropin is suggested to improve intestinal adaptation in this condition by directly or indirectly acting on the intestine.

Emerging Therapies in Short Bowel Syndrome Market

Apraglutide: VectivBio 

Apraglutide, a long-acting glucagon-like peptide-2 (GLP-2) analog, is developed for once-weekly subcutaneous dosage. It has the potential to enhance fluid and nutritional absorption by the remaining intestine in patients with short bowel syndrome, intestinal insufficiency, or intestinal failure. Apraglutide targets the underlying issue of inadequate absorptive capacity. The medication enhances fluid, energy, and electrolyte absorption. Improved intestinal absorption may alleviate malabsorption symptoms and lessen the need for parenteral support. Apraglutide, administered once weekly, is predicted to increase treatment compliance and quality of life.

Glepaglutide: Zealand Pharma

Glepaglutide is a long-acting GLP-2R agonist in clinical trials for short bowel syndrome. Glepaglutide stimulates crypt cell proliferation and inhibits villus cell death, resulting in enhanced mucosal expansion. The use of glepaglutide twice a week for the treatment of short bowel syndrome with intestinal failure is currently being evaluated by the U.S. FDA. The regulatory filing is based on the findings of four clinical trials that examined the potential of glepaglutide to minimize or eliminate the need for parenteral support in short bowel syndrome patients with intestinal failure.

HM15912: Hanmi Pharmaceutical

HM15912, a long-acting glucagon-like peptide 2 (GLP-2) analog, is an innovative drug with proprietary platform technology LAPscovery that is being developed as the world's first once-monthly dosage formulation based on GLP-2's increased persistence in the body and excellent villus growth-promoting effect. HM15912 boosts intestinal growth and absorption capacity in patients with short bowel syndrome. This medication has a strong small bowel hypertrophic effect in rodents and requires less dosage than other GLP-2 analogs on the market or in clinical research.

ALC-078: Alcresta Therapeutics

ALC-078, designed by Alcresta Therapeutics, is an experimental enzyme therapy aimed to treat short bowel syndrome. The ALC-078 is a single-use cartridge that connects to an enteral feeding device. The cartridge contains immobilized lipase, a digestive enzyme that converts fats in the formula into fatty acids and monoglycerides. The lipase remains in the cartridge and is not consumed by the patient. ALC-078 can enhance fat and nutrient absorption, potentially reducing the need for parenteral nutrition.

NST-6179: NorthSea Therapeutics

NST-6179, a medium chain fatty acid analog manufactured by NorthSea Therapeutics, works by facilitating intestinal uptake to treat intestinal failure-associated liver disease and short bowel syndrome. NST-6179 is a lipid-based therapy that focuses on the gut's ability to absorb and metabolize lipids, which is frequently compromised in people with SBS due to reduced intestinal surface area. The substance is a fatty acid-based formulation intended to increase lipid absorption in the remaining section of the small intestine. This helps to compensate for the malabsorption associated with SBS, which occurs when the body's gut is insufficient to absorb critical nutrients, particularly lipids and fat-soluble vitamins.

Detailed list of emerging therapies in Short Bowel Syndrome is provided in the final report.

Leading Companies in the Short Bowel Syndrome Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global short bowel syndrome market, several leading companies are at the forefront of developing integrated platforms to enhance the management of short bowel syndrome. Some of the major players include Takeda, Emmaus Medical, and Merck Serono. These companies are driving innovation in the short bowel syndrome market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for the illness.

​In September 2023, Takeda announced that it had completed a phase III trial study evaluating teduglutide in patients with short bowel syndrome (in infants, children, adolescents, adults, and the elderly) in Japan.

Key Players in Short Bowel Syndrome Market:

The key players in the Short Bowel Syndrome market who are in different phases of developing different therapies are Takeda, Emmaus Medical, Merck Serono, VectivBio, Zealand Pharma, Hanmi Pharmaceutical, Alcresta Therapeutics, NorthSea Therapeutics, and Others.

Regional Analysis:

The major markets for short bowel syndrome include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for short bowel syndrome while also representing the biggest market for its treatment. This can be attributed to various advancements in regenerative medicine, such as stem cell therapies and tissue engineering, which help to provide long-term solutions by promoting intestinal regeneration.

Moreover, one key driver is the introduction of innovative therapies, particularly GLP-2 analogs like teduglutide, which enhance nutrient absorption and reduce dependence on parenteral nutrition. These treatments improve the quality of life for SBS patients, providing more effective management of the condition compared to traditional therapies.

Besides this, the U.S. healthcare system also supports the development of new therapies through incentives like orphan drug designations and fast-track approvals, encouraging pharmaceutical companies to invest in SBS treatments. Furthermore, improved diagnostic tools and greater awareness of the condition are helping identify patients earlier, contributing to better treatment outcomes​.

Recent Developments in Short Bowel Syndrome Market:

• In October 2024, Ironwood Pharmaceuticals, Inc. announced that it will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course from subgroup analyses of the primary endpoint of the pivotal Phase III clinical trial, STARS, which evaluated the treatment effect of apraglutide in adults with short bowel syndrome with intestinal failure based on baseline demographics and disease-specific characteristics. The results suggest that apraglutide had a consistent therapeutic effect across all categories, including gender, age, body weight, geography, race, ethnicity, and SBS features such as length of remnant bowel. These findings support previously published positive findings from the phase III pivotal trial.
• In December 2023, Zealand Pharma reported that it had submitted a New Drug Application (NDA) to the U.S. FDA for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome requiring parenteral support.
• In March 2023, Alcresta Therapeutics announced the release of preclinical results from its study product ALC-078 in a porcine short bowel syndrome model. The study performed at Boston Children's Hospital found that therapy with ALC-078 was related to lower dependence on parenteral nutrition, greater enteral nutrition progress, and a rise in intestinal length, which is a sign of intestinal adaptability.
   

Key information covered in the report.

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the short bowel syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the short bowel syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report offers a comprehensive analysis of current short bowel syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800